I was fortunate to be involved in Andrew's care.
He endured several lines of therapy,
he was brave and he was willing to jump in
when patients with HLRCC never had tried any of these drugs.
We're pushing forward and we're hoping UCLA
will make you proud as the west coast center of excellence
for this disease.
What is going on here at UCLA is just cutting-edge.
We really wanna understand at the molecular level
how these tumors are growing and how we can target that.
I think today's word is collaboration.
Anybody who's fighting a rare disease knows how difficult it is,
but my goodness, the collaboration that's going on here is impressive.
I'm so glad we came out to UCLA.